In this in vivo model, we found that the expression of ODF2L was dramatically increased in tumor cells from the AZD1775-treated group, as validated by quantitative reverse transcription PCR (RT-qPCR) and immunoblotting (Figure 1F). Here, ODF2L is linked to neoplasm.